异丙托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病稳定期的临床效果及对患者IL-6、SAA水平的影响

Clinical effect of ipratropium bromide combined with salmeterol xinafoate and fluticasone propionate in the treatment of chronic obstructive pulmonary disease at stable stage and its influences on IL-6 and SAA levels of patients

目的探究异丙托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病(COPD)稳定期的临床效果及对患者白细胞介素-6(IL-6)、血清淀粉样蛋白A(SAA)水平的影响。方法选择2020年5月至10月我院收治的170例COPD稳定期患者,按照随机表法将其分为A组(n=85,沙美特罗替卡松治疗)、B组(n=85,异丙托溴铵联合沙美特罗替卡松治疗)。比较两组的治疗效果。结果治疗后,两组的第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、FEV_(1)/FVC均增大,且B组显著大于A组(P<0.05)。治疗后,两组的IL-6、SAA水平均降低,且B组显著低于A组(P<0.05)。B组的治疗总有效率为94.12%,显著高于A组的82.35%(P<0.05)。结论异丙托溴铵联合沙美特罗替卡松治疗COPD稳定期的临床效果显著,可改善患者的肺功能指标及血清炎性因子水平,值得临床推广应用。

Objective To explore the clinical effect of ipratropium bromide combined with salmeterol xinafoate and fluticasone propionate in the treatment of chronic obstructive pulmonary disease(COPD)at stable stage and its influences on interleukin-6(IL-6)and serum amyloid A(SAA)levels of patients.Methods A total of 170 patients with COPD at stable stage admitted in our hospital from May to October 2020 were selected and divided into group A(n=85,salmeterol xinafoate and fluticasone propionate treatment)and group B(n=85,ipratropium bromide combined with salmeterol xinafoate and fluticasone propionate treatment)according to the random table method.The therapeutic effects of the two groups were compared.Results After treatment,the forced expiratory volume in one second(FEV_(1)),forced vital capacity(FVC)and FEV_(1)/FVC in the two groups increased,and those in the group B were significantly greater than the group A(P<0.05).After treatment,the levels of IL-6 and SAA in the two groups decreased,and those in the group B were significantly lower than the group A(P<0.05).The total effective rate of treatment in the group B was 94.12%,which was significantly higher than 82.35% in the group A(P<0.05).Conclusion Ipratropium bromide combined with salmeterol xinafoate and fluticasone propionate in the treatment of COPD at stable stage has a significant clinical effect,it can improve the pulmonary function indexes and serum inflammatory factor levels of patients,which is worthy of clinical promotion and application.